5 Key Takeaways

• 1

  Switching between biologic drug classes in adults with psoriasis improved skin clearance in both the short and long term.

• 2

  Interclass switching was associated with significant short-term Psoriasis Area and Severity Index gains within 4 weeks.

• 3

  The greatest improvements were observed when switching from TNF-α inhibitors to IL-23p19 inhibitors.

• 4

  Safety outcomes were generally comparable, though some switches were linked to slightly higher infection rates.

• 5

  The study's limitations included variations in trial definitions and insufficient data for some comparisons.